Neoplasms

Symptoms and General Pathology

All Conditions

Neoplastic Processes

Antineoplastic Agents

All Drugs and Chemicals

Pharmaceutical Solutions

Micronutrients

Hematinics

Vitamins

Pemetrexed

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Enzyme Inhibitors

Folinic Acid

Folate

Vitamin B9

TRC102 + pemetrexed

Bryan Leigh, MD

This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.

Study of TRC102 in Combination With Pemetrexed in Cancer Patients

Open Label Phase 1 Dose Finding Study of TRC102 in Combination With Pemetrexed in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable

Tracon Pharmaceuticals Inc.

Bryan Leigh, MD, Medical Monitor

Skin and Connective Tissue Diseases

Breast Neoplasms

Pathologic Complete Response

Breast Diseases

Skin Diseases

Patients randomized into this group receiving PTC test and choose regimens according to this test results

Patients randomized into this group receiving routine regimens according to subtypes

Intervention Description：Neoadjuvant therapy regimen of patients in the PTC group is guided by PTC drug sensitivity results. After operation, adjuvant targeted therapy for pCR patients is based on original treatment, adjuvant targeted therapy for non-pCR patients is based on a secondary PTC drug sensitivity results.

patient-derived tumor-like cell clusters drug sensitivity test

Xingfei Yu, M.D.

Patients with breast cancer meet criteria for enrollment are randomized into PTC group or control group. The neoadjuvant therapy regimens are guided by PTC test in the PTC group. The regimens in control group are included of (dd)EC-T for HER2 negative subtype, TCH(P) or EC-TH(P) for HER2 positive subtype. We compared the pCR rate between two groups as the primary endpoint.

1. Before neoadjuvant therapy, all samples will be obtained by core needle biopsy for PTC drug sensitivity test.
2. After obtaining drug sensitivity results and confirming ER/PR and HER2 expression state, all recruited patients will be randomized into the PTC group or the routine treatment group, according to the method of random number table.
3. Beijing Cornerstone Life Science and Technology Co., Ltd. is responsible for gene sequencing and PTC drug sensitivity test for biological samples. All samples for the study are clinical residuals and will be used in the study, store or destruction is unapplicable.
4. Neoadjuvant therapy regimen in the PTC group is guided by PTC drug sensitivity results, and regimen in the routine treatment group is based on clinical guideline, such as (dd)EC-T for HER2 negative breast cancer, and TCH(P) or EC-TH(P) for HER2 positive breast cancer. All neoadjuvant therapy will be completed before operation if without PD.
5. According to postoperative pathological remission, pCR patients in two groups continued to complete adjuvant targeted therapy based on original treatment. For non-pCR patients in the PTC group, PTC drug sensitivity test will be done again to guide adjuvant therapy, for non-pCR patients in the routine treatment group, Capecitabine for HER2 negative breast cancer, and T-DM1 or H(P) will be selected.
6. All patients will be received radiotherapy or endocrine therapy if necessary.

PTC Guiding Neoadjuvant Treatment in Breast Cancer

Neoadjuvant Therapy for Breast Cancer Based on Patient-derived Tumor-like Cell Clusters Advanced Drug Sensitization Regimens: a Phase II Randomized Controlled Clinical Study

survive with neither invasive recurrence nor new invasive diseases

Zhejiang Cancer Hospital

Doctor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of TRC102 in Combination With Pemetrexed in Cancer Patients	NCT00692159	Neoplasm	TRC102 + pemetr...	18 Years -	Tracon Pharmaceuticals Inc.
PTC Guiding Neoadjuvant Treatment in Breast Cancer	NCT05103293	Pathological Co...	patient-derived...	18 Years - 70 Years	Zhejiang Cancer Hospital

Spots Global Cancer Trial Database for pathological conditions, signs and symptoms